Patent intelligence · US
US 8916528
Compositions containing resveratrol and nucleotides
Compositions containing resveratrol and nucleotides
Patent details — US 8916528
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 23, 2014
- Expiration
- Dec 18, 2034
- Applicant
- RESVERATROL PARTNERS, LLC
- Claims
- 19
- CPC classes
- A61K, A61K31/05, A61K31/185, A61K31/352
Quick answer
US 8916528 (Compositions containing resveratrol and nucleotides) is held by RESVERATROL PARTNERS, LLC. Status: granted. Granted Dec 23, 2014. Expires Dec 18, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RESVERATROL PARTNERS, LLC
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/05, A61K31/185, A61K31/352, A61K31/353, A61K31/6615
More from RESVERATROL PARTNERS, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 8916528?
US 8916528 (Compositions containing resveratrol and nucleotides) is held by RESVERATROL PARTNERS, LLC. Status: granted. Granted Dec 23, 2014. Expires Dec 18, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8916528?
RESVERATROL PARTNERS, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 8916528 expire?
Our index shows an expiration date of Dec 18, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.